- FAMAR has signed an agreement to acquire a sterile manufacturing facility in Homburg, Germany, from MiP Pharma.
- The acquisition expands FAMAR’s capabilities in aseptic and lyophilised fill & finish, bringing its European site count to seven.
FAMAR, a portfolio company of private equity investor MidEuropa, has agreed to acquire a sterile manufacturing site in Homburg (Saar), Germany, from MiP Pharma. The move enhances FAMAR’s position in the CDMO sector by strengthening its capabilities in high-value dosage forms, particularly in aseptic and lyophilised fill & finish operations.
The newly acquired Homburg facility brings FAMAR’s total European manufacturing sites to seven. This expansion supports the company’s aim to offer scalable and flexible contract manufacturing solutions across multiple dosage forms.
Konstantinos Rengis, CEO of FAMAR, commented, “The Homburg facility offers us the opportunity to expand our business with international clients. There is scarcity in high-quality sterile infrastructure in Europe and the investment will provide us immediate capacity for our growing business.”
Backed by MidEuropa, which has a long-standing presence in Central Europe, FAMAR is accelerating its growth in value-added formulations. Matthew Strassberg, Partner and Head of Healthcare at MidEuropa, stated the acquisition reflects their ongoing commitment to support FAMAR’s international expansion strategy.
